Technical Data
8 Feb 2021

Neofact® - Feasibility study

PDF 553 kB
Download

In the clinical study carried out at the University Hospital Tübingen, 20 premature infants (gestational age ≥26 + 0/7) were administered surfactant Alveofact® (45 mg / mL; Lyomark Pharma, Oberhaching, Germany) using the new LISA application aid Neofact®. The aim of developing Neofact® was to enable a simple and gentle process for surfactant application that works without the use of Magill forceps. Neofact® makes surfactant application easy and is also suitable for all gestational ages. This was confirmed in the study and the results of the study are convincing. An extremely high success rate could be achieved (95%), complications seemed rear.

Further information on the study can be found: https://pubmed.ncbi.nlm.nih.gov/33023914/

Content provided by our supplier

Lyomark Pharma GmbH

  • DE
  • 2015
    On CPHI since
Company types
Distributor/Import Export
Licensee
View company profile

Other Content from Lyomark Pharma GmbH (1)

  • Neofact - Clinical evaluation of an applicator for surfactant administration

    News Neofact - Clinical evaluation of an applicator for surfactant administration

    Neofact, by Lyomark Pharma, is a medical device for neonates suffering from RDS. 
    This study shows that the LISA method (less invasive administration) via Neofact® appears feasible. 

    Neofact® makes surfactant application easy and can also be used at any gestational age.

    https://pubmed.ncbi.nlm.nih.gov/33023914/
    23 Apr 2021